Treatment of Anemia in Diabetic Subjects With CKD

Summary

The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline by Week 17.

Timeline

Start

2005-03

Primary completion

—

Completion

2005-09

Outcome

Outcome not reported

Stopped (Enrollment): “This study was stopped for slow enrollment after enrolling only 11 of 180 patients in six months time.”

Publications

• Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 13;2(2):CD010590. doi: 10.1002/14651858.CD010590.pub3.

Drugs

Indications